Aktis Oncology Appoints Industry R&D Veteran Glenn Gormley to Board, Establishes Science & Tech Committee

summarizeSummary

Aktis Oncology appointed Dr. Glenn Gormley, a seasoned R&D executive, to its Board of Directors and as Co-Chair of a new Science and Technology Committee, while two existing directors are resigning.

check_boxKey Events

• New Director Appointment

  Glenn Gormley, MD, PhD, a veteran with over three decades of biopharmaceutical R&D leadership experience, including roles at Daiichi Sankyo, Novartis, and AstraZeneca, was appointed as a Class I director.

• Strategic Committee Formation

  Dr. Gormley was appointed Co-Chairperson of the newly created Science and Technology Committee of the Board, alongside current board member Ken Herrmann, MD, PhD.

• Director Resignations

  Helen S. Kim and Oleg Nodelman notified the Board of their decision to resign, effective May 20, 2026. The company stated their resignations are not due to any disagreement.

• Equity Compensation

  Dr. Gormley received an option to purchase 37,866 shares of common stock, vesting over three years, as part of his compensation package.

auto_awesomeAnalysis

Aktis Oncology has strategically strengthened its board with the appointment of Dr. Glenn Gormley, a highly experienced biopharmaceutical R&D leader. His extensive background, including leading Daiichi Sankyo's ADC platform development, is directly relevant to Aktis's focus on miniprotein radioconjugates. His role as Co-Chair of the newly formed Science and Technology Committee signals a heightened focus on scientific oversight and innovation, which is crucial for a clinical-stage oncology company. While two directors are resigning, the company states these departures are not due to disagreements and are offset by the addition of Dr. Gormley's specialized expertise, which is vital as Aktis advances its pipeline candidates.